Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis
Status:
NOT_YET_RECRUITING
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate, through a multicenter, prospective, double-blind, randomized, placebo-controlled clinical trial, whether immunosuppressive therapy improves target lesion-related cardiovascular outcomes compared to placebo treatment in patients with Rapid rEcurrence of Coronary Unexplained in-stent Restenosis (RECUR).
Phase:
NA
Details
Lead Sponsor:
China National Center for Cardiovascular Diseases
Collaborators:
Chinese Academy of Medical Sciences, Fuwai Hospital The First Hospital of Jilin University